Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

Market Cap	22.79B +0.5%
Revenue (ttm)	6.01B +2.7%
Net Income	1.07B -8.9%
EPS	1.06 -9.3%
Shares Out	1.02B
PE Ratio	21.15
Forward PE	17.67
Dividend	0.40 (1.80%)
Ex-Dividend Date	May 14, 2025

Volume	12,317,980
Average Volume	10,649,892
Open	21.52
Previous Close	22.22
Day's Range	21.52 - 22.62
52-Week Range	20.74 - 29.30
Beta	-0.17
RSI	52.10
Earnings Date	Apr 18, 2026

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, olanzapine tablets, midazolam hydrochloride oral solution, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 6,003
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002262

Financial Performance

In 2025, SHE:002262's revenue was 5.91 billion, an increase of 3.75% compared to the previous year's 5.70 billion. Earnings were 1.06 billion, a decrease of -7.54%.